Summary

The MEA respiratory tract infection treatment market size is expected to grow from US$ 2.09 billion in 2023 to US$ 2.97 billion by 2031; it is estimated to register a CAGR of 4.50% from 2023 to 2031.

Surge in Demand for OTC Products to Treat Respiratory Infections Opportunity for Growth of MEA Respiratory Tract Infection Treatment Market

A vast number of consumers seek accessible and convenient solutions for common respiratory symptoms such as cough, congestion, and sore throat. This approach empowers individuals who are not suffering from life-threatening diseases to closely monitor and control their health. It also allows manufacturers, pharmacies, and healthcare providers to make their product offerings more suitable for over-the-counter (OTC) applications, educate consumers on self-care practices, and improve access to treatment options providing relief from various symptoms. The burgeoning popularity of OTC respiratory remedies underlines the importance of promoting respiratory health awareness, fostering self-management strategies and a collaborative healthcare ecosystem. By leveraging the rising popularity of OTC respiratory products, the respiratory tract infection treatment market stakeholders in the MEA can enhance patient engagement, promote preventive healthcare measures, and address the evolving healthcare needs of diverse populations. Thus, the increasing demand for OTC products to manage respiratory infections represents a significant opportunity for the MEA respiratory tract infection treatment market.

Drug -Based Insights

In terms of drug, the antibiotics segment held the largest MEA respiratory tract infection treatment market share in 2023. The same is anticipated to register the highest CAGR during 2023–2031. Respiratory tract infections encompass a range of ailments, including bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens.

Disease Indication -Based Insights

Based on disease indication, the lower respiratory tract infection segment held a larger market share in 2023. It is further anticipated to register a higher CAGR from 2023 to 2031. Lower respiratory tract infections (LRTIs) are infections that affect the lungs and bronchial tubes, typically caused by bacterial, viral, or fungal pathogens, among others.

Route Of Administration -Based Insights

By route of administration, the oral segment held a larger share of the MEA respiratory tract infection treatment market; the same segment is anticipated to register a higher CAGR during 2023–2031. Oral antibiotics such as amoxicillin, azithromycin, or doxycycline are frequently prescribed to combat bacterial pathogens causing respiratory tract infections.

Age Group -Based Insights

In terms of age group, the adult segment held a larger share of the MEA respiratory tract infection treatment market in 2023. The pediatrics segment is anticipated to register a higher CAGR during 2023–2031. The high prevalence of respiratory tract infections among children is a key factor driving the need for effective treatment options.

Distribution Channel -Based Insights

In terms of distribution channel, the hospital pharmacies segment is anticipated to account for a significant market share during 2023–2031. Hospital pharmacies serve as key components of a healthcare system; they particularly play a vital role in the management of acute and severe respiratory tract infections, which require intravenous or intramuscular administration of medications.

A few of the major primary and secondary sources referred to while preparing the report on the MEA respiratory tract infection treatment market are the Dubai Health Authority, Saudi Initiative for Asthma, Saudi Thoracic Society.

ページTOPに戻る

Table of Contents

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Respiratory Tract Infection Treatment Market Landscape
4.1 Overview
4.2 PEST Analysis
5. MEA Respiratory Tract Infection Treatment Market – Key Market Dynamics
5.1 MEA Respiratory Tract Infection Treatment Market – Key Market Dynamics
5.2 Key Market Drivers
5.2.1 Rising Cases of Respiratory Infections in Middle East
5.2.2 Increasing Awareness Related to Respiratory Tract Infections
5.3 Key Market Restraints
5.3.1 Lack of Research Focused on Respiratory Therapeutics
5.4 Key Market Opportunities
5.4.1 Surge in Demand for OTC Products to Treat Respiratory Infections
5.5 Future Trends
5.5.1 Advent of Antiviral Treatment for MERS
5.6 Impact of Drivers and Restraints:
6. MEA Respiratory Tract Infection Treatment Market Analysis
6.1 MEA Respiratory Tract Infection Treatment Market Revenue (US$ Million), 2023–2031
7. MEA Respiratory Tract Infection Treatment Market Analysis – by Drugs
7.1 Antibiotics
7.1.1 Overview
7.1.2 Antibiotics: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.2 NSAIDs
7.2.1 Overview
7.2.2 NSAIDs: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Cough Suppressants
7.3.1 Overview
7.3.2 Cough Suppressants: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Nasal Decongestants
7.4.1 Overview
7.4.2 Nasal Decongestants: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
8. MEA Respiratory Tract Infection Treatment Market Analysis – by Disease Indication
8.1 Lower Respiratory Tract Infection
8.1.1 Overview
8.1.2 Lower Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Upper Respiratory Tract Infection
8.2.1 Overview
8.2.2 Upper Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
9. MEA Respiratory Tract Infection Treatment Market Analysis – by Route Of Administration
9.1 Oral
9.1.1 Overview
9.1.2 Oral: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Parenteral
9.2.1 Overview
9.2.2 Parenteral: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
10. MEA Respiratory Tract Infection Treatment Market Analysis – by Age Group
10.1 Pediatrics
10.1.1 Overview
10.1.2 Pediatrics: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Adults
10.2.1 Overview
10.2.2 Adults: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
11. MEA Respiratory Tract Infection Treatment Market Analysis – by Distribution Channel
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12. MEA Respiratory Tract Infection Treatment Market – Country Analysis
12.1 Middle East and Africa
12.1.1 MEA Respiratory Tract Infection Treatment Market Breakdown by Countries
12.1.2 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis – by Country
12.1.3 MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2030
12.1.3.1 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis – by Country
12.1.3.2 Saudi Arabia
12.1.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12.1.3.3.1 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
12.1.3.3.2 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
12.1.3.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
12.1.3.3.4 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
12.1.3.3.5 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
12.1.3.4 South Africa
12.1.3.5 South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12.1.3.5.1 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
12.1.3.5.2 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
12.1.3.5.3 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
12.1.3.5.4 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
12.1.3.5.5 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
12.1.3.6 UAE
12.1.3.7 UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12.1.3.7.1 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
12.1.3.7.2 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
12.1.3.7.3 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
12.1.3.7.4 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
12.1.3.7.5 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
12.1.3.8 Rest of MEA
12.1.3.9 REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)
12.1.3.9.1 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
12.1.3.9.2 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
12.1.3.9.3 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
12.1.3.9.4 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
12.1.3.9.5 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
13. Company Profiles
13.1 Abbott Laboratories
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Teva Pharmaceutical Industries Ltd
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Sanofi SA
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Boehringer Ingelheim International GmbH
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 AstraZeneca Plc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Alembic Pharmaceuticals Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 GSK Plc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Novartis AG
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. Hoffmann-La Roche Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Gulf Pharmaceutical Industries Co
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms